Disclosures

Editorial Board Member: Dr Andrew Gennery

Watson Reader/Honorary Consultant in Paediatric Immunology & Haematopoeitic Stem Cell Transplantation. Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK.

Disclosures: Dr Gennery has delivered lectures as part of an ‘in- house’ education staff to GSK Staff – Haematopoietic Stem Cell Transplantation for Primary Immunodeficiencies

Editorial Board member: Dr Robbert Bredius

MD PhD, Paediatric Immunologist – Infectious Disease – Stem Cell Transplant Dr. Department of Paediatrics, Immunology section, Hematology and Stem Cell Transplantation, Leiden University Medical Centre, The Netherlands.

Disclosures: Dr Bredius has delivered industry symposia presentations funded by GSK

Expert Interviewee: Professor Marina Cavazzana

Head of the Biotherapy Department, Necker Chidren’s Hospital, Assistance Publique-Hôpitaux de Paris, France

Disclosures: Professor Cavazzana stated that she has no relationships to disclose

Expert Interviewee: Professor Bobby Gaspar

Professor of Paediatrics and Immunology; Consultant in Paediatric Immunology; Head, Rare Diseases Theme; Head, Molecular and Cellular Immunology Section. UCL Great Ormond Street Institute of Child Health, UK.

Disclosures: Professor Gaspar is founder and Chief Scientific Officer for Orchard Therapeutics, a new company that is developing a lentiviral gene therapy approach for ADA-SCID.

Share This: